TuHURA Biosciences Inc (HURA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $2.11 (+0.96%), Market cap $0.15B, 52-week low–high $0.44 ~ $3.31.
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. It is also preparing to initiate a single randomized placebo-controlled which is in Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda; and Delta receptor technology to develop tumor microenvironment modulators in the form of first-in-class bi-functional and bi-specific antibody-drug conjugates targeting Myeloid Derived Suppressor Cells. In addition, the company is also
Financial statements, price targets, institutional (13F) holdings and related news for TuHURA Biosciences Inc are updated in real time on BlackAll Trade.
TuHURA Biosciences Inc trades at $2.11 (+0.96%). Real-time quotes and charts are available on BlackAll Trade.
TuHURA Biosciences Inc has a market cap of about $0.15B.
TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0,